European Addiction Research

Pavarin R.M.a,b· Consonni D.c· Lucchi F.d· Pandolfi P.e· Marani S.a· Palmese F.f· Domenicali M.f

Author affiliations

aEpidemiological Monitoring Center on Addiction, Azienda USL Bologna, Department of Mental Health and Addictions, Azienda USL Bologna, Bologna, Italy
bItalian Society on Addiction (SITD), Rome, Italy
cEpidemiology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
dDepartment of Mental Health and Addictions, Azienda USL di Bologna, Bologna, Italy
ePublic Health Department, Azienda USL Bologna, Bologna, Italy
fDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: May 27, 2022
Accepted: October 02, 2022
Published online: November 30, 2022

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 2

ISSN: 1022-6877 (Print)
eISSN: 1421-9891 (Online)

For additional information: https://www.karger.com/EAR

Abstract

Background: People with substance or alcohol use disorders (SUDs/AUDs) are likely to be more vulnerable to COVID-19 infection than the general population, but the evidence of COVID-19-related mortality in these patients is unclear. Objectives: The aim of the study was to verify whether patients with AUD and SUD have a higher mortality rate for COVID-19-related mortality compared to the general population. Method: We performed a follow-up study to assess mortality in 2020 in a cohort of patients diagnosed for the first time with AUDs or SUDs at the Public Health Services in the metropolitan area of Bologna (Northern Italy) from 2009 to 2019. Results: SUDs/AUDs patients present an excess mortality with respect to the general population for all causes of death and for COVID-19-related mortality. Conclusions: Our data support the need for prevention strategies in SUDs/AUDs patients such as vaccinations.

© 2022 S. Karger AG, Basel

References Chow N, Fleming-Dutra K, Gierke R, Hall A, Hughes M, Pilishvili T, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019: United States, february 12-march 28, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr;69(13):382–6. Benzano D, Ornell F, Schuch JB, Pechansky F, Sordi AO, von Diemen L, et al. Clinical vulnerability for severity and mortality by COVID-19 among users of alcohol and other substances. Psychiatry Res. 2021 Jun;300:113915. Testino G. Are patients with alcohol use disorders at increased risk for Covid-19 infection?Alcohol Alcohol. 2020 Jun 25;55(4):344–6. Pavarin RM, Fabbri C, De Ronchi D. COVID-19 hospitalization rates in individuals with substance or alcohol use disorders. Psychiatry Res. 2022 May;311:114521. Hasin DS, Fink DS, Olfson M, Saxon AJ, Malte C, Keyes KM, et al. Substance use disorders and COVID-19: an analysis of nation-wide Veterans Health Administration electronic health records. Drug Alcohol Depend. 2022 May 1;234:109383. Vai B, Mazza MG, Delli Colli C, Foiselle M, Allen B, Benedetti F, et al. Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. Lancet Psychiatry. 2021 Sep;8(9):797–812. Fond G, Nemani K, Etchecopar-Etchart D, Loundou A, Goff DC, Lee SW, et al. Association between mental health disorders and mortality among patients with COVID-19 in 7 countries: a systematic review and meta-analysis. JAMA Psychiatry. 2021 Nov 1;78(11):1208–17. Reilev M, Kristensen KB, Pottegård A, Lund LC, Hallas J, Ernst MT, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020 Oct 1;49(5):1468–81. Abdul-Rahman AK, Card TR, Grainge MJ, Fleming KM. All-cause and cause-specific mortality rates of patients treated for alcohol use disorders: a meta-analysis. Subst Abus. 2018;39(4):509–17. Dwyer-Lindgren L, Bertozzi-Villa A, Stubbs RW, Morozoff C, Shirude S, Unützer J, et al. Trends and patterns of geographic variation in mortality from substance use disorders and intentional injuries among US counties, 1980–2014. JAMA. 2018 Mar 13;319(10):1013–23. Article / Publication Details

First-Page Preview

Received: May 27, 2022
Accepted: October 02, 2022
Published online: November 30, 2022

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 2

ISSN: 1022-6877 (Print)
eISSN: 1421-9891 (Online)

For additional information: https://www.karger.com/EAR

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.